Eli Lilly & Co (1LLY) AI Stock Analysis

9 Followers

Eli Lilly & Co

(Milan:1LLY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Exceptional revenue growthRapid growth across leading metabolic medicines and multiple therapeutic areas indicates strong demand, expanding patient adoption, and increasing commercial scale. Broadening growth beyond a single product can support durable revenue momentum and strengthen Lilly’s position over the next several quarters.

Negative Factors

Persistent pricing pressureLower realized prices can constrain revenue quality and margin expansion even when prescription volumes grow. Continued payer and government pricing pressure may require Lilly to depend increasingly on sustained volume gains, product launches, and mix improvements to preserve earnings momentum.

Eli Lilly & Co (1LLY) vs. iShares MSCI Italy ETF (EWI)

Market Cap: EUR 1.33T
Dividend Yield: 0.45%
Average Volume (3M): 425
Price to Earnings (P/E): 45.9
Beta (1Y): 0.45
Revenue Growth: 39.01%
EPS Growth: 44.35%
Country: Italy
Employees: 50,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Eli Lilly & Co Business Overview & Revenue Model

Company Description

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This e...

Eli Lilly & Co Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:9.97%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was strongly positive. Lilly reported 39% quarterly revenue growth, raised full-year guidance, delivered broad product and international growth, demonstrated strong uptake for Mounjaro, Zepbound, the Medicare Bridge program, and Foundayo, and advanced regulatory, clinical, manufacturing, and business-development initiatives. The main challenges were U.S. and expected future pricing pressure, nonrecurring 2026 revenue benefits, higher investment spending, oral-adherence uncertainty, adverse-event discontinuations at the highest Olora-TZP dose, and ongoing regulatory and reimbursement timing. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Q3 Revenue Growth

Q3 revenue grew 39% compared with Q3 2025, or nearly $7 billion, driven by Mounjaro, Zepbound, and strong momentum across therapeutic areas. Key product revenue increased by over $6 billion.

Negative Updates

U.S. Price Declines

U.S. revenue increased 34%, but this was partially offset by a 7% decline in price. Excluding a favorable adjustment to rebate and discount estimates, U.S. price declined 10%.

Company Guidance

For 2026, Lilly expects full year revenue to be between $91 and $92 billion, non GAAP performance margin to be between 52.5%, and non GAAP earnings per share of $35 to $36, reflecting an increase of $4.07 per share at the midpoint of the range before updates to the Q3 acquired IPR&D charges of $4.57 per share. For 2027, Lilly expects sustained volume growth in the incretin market, the full year impact of the Medicare GLP-1 bridge access, and the launch of Foundayo in type 2 diabetes in The US; outside The US, it expects Mounjaro's leadership position to continue and expects to launch Foundayo, which will drive additional market growth. Lilly expects net realized price to be a headwind more than offset by volume growth, while noting that 2026 revenue benefited from approximately $2 billion of 1-time items primarily related to milestones payments and changes in estimates for rebates and discounts that it does not expect to recur; it expects a global rollout of Foundayo in all major markets in 2027.

Eli Lilly & Co Risk Analysis

Eli Lilly & Co disclosed 16 risk factors in its most recent earnings report. Eli Lilly & Co reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Eli Lilly & Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IT:1LLY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVO	78Outperform	$180.31B	10.88	59.09%	4.26%	13.21%	12.68%
AMGN	75Outperform	$249.37B	27.53	85.59%	2.08%	8.62%	33.48%
ABBV	71Outperform	$505.40B	50.57	-202.50%	2.35%	10.68%	338.08%
PFE	67Neutral	$170.99B	43.56	4.60%	5.59%	1.34%	-58.96%
MRK	63Neutral	$356.93B	153.41	5.10%	2.26%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

IT:1LLY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IT:1LLY	Eli Lilly And Company	1273.40	463.24	57.18%
AMGN	Amgen Inc	478.48	171.41	55.82%
MRK	Merck & Company	150.36	67.03	80.43%
NVO	Novo Nordisk	42.18	-2.80	-6.22%
PFE	Pfizer Inc	30.79	7.57	32.60%
ABBV	Abbvie	294.83	82.16	38.63%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Eli Lilly & Co AI Stock Analysis